MONOGRAPH

Cefalexin Monograph - Paediatric

Scope (Staff):	Medical, Pharmacy, Nursing
Scope (Area):	All Clinical Areas

Child Safe Organisation Statement of Commitment

CAHS commits to being a child safe organisation by applying the National Principles for Child Safe Organisations. This is a commitment to a strong culture supported by robust policies and procedures to reduce the likelihood of harm to children and young people.

This document should be read in conjunction with this DISCLAIMER

DRUG CLASS

Moderate spectrum cephalosporin.[1, 2]

INDICATIONS AND RESTRICTIONS

Cefalexin is indicated in the treatment of methicillin sensitive *Staphylococcus aureus* (MSSA) and streptococcal infections and in the treatment and prophylaxis of urinary tract infections.[2-4]

Oral: Unrestricted (green) antibiotic

This is not a restricted agent. Follow standard ChAMP guidelines where appropriate.

CONTRAINDICATIONS

- Hypersensitivity to cefalexin, a high-risk allergy to cephalosporins or any component of the formulation.[2, 3, 5, 6]

PRECAUTIONS

- Cefalexin may be prescribed in selected patients with high risk allergy to another Beta-lactam sub-class (e.g. some penicillins, carbapenems) in discussion with immunology.[2, 3, 5]
- In patients with a previous low risk reaction to cephalexin or another cephalosporin (delayed rash [>1hr after initial exposure] without mucosal or systemic involvement) the risk of subsequent reaction is low. Re-challenge may be acceptable in discussion with immunology.[7, 8]
- High cefalexin levels in the presence of renal impairment may increase the risk of seizures.[9]

FORMULATIONS

Listed below are products available at PCH, other formulations may be available, check with pharmacy if required:

- 250 mg/5mL powder for oral suspension
- 250 mg and 500 mg capsules

Imprest location: Formulary One

DOSAGE & DOSAGE ADJUSTMENTS

Neonates: Refer to Neonatal Medication Protocols

Children (> 4 weeks to 18 years):

Oral:

- **Usual dose:** 20 mg/kg/dose (to a maximum of 750 mg) every 8 hours.[10]
- **Severe infections including bone and joint infections:** 37.5 to 45 mg/kg/dose (to a maximum of 1500 mg) 8 hourly.[10, 11]
- **Invasive Group A Streptococcal (iGAS) infection post exposure prophylaxis:** 25 mg/kg/dose (to a maximum of 1000 mg) given twice daily for 10 days.[4]
- **UTI prophylaxis:** 12.5 mg/kg/dose (to a maximum of 250 mg) given once daily at night.[1, 2]

Note: Some texts recommend a lower standard dose of cefalexin given 6 hourly. At PCH doses < 12.5 mg/kg/dose are rarely given except for dose adjustment in renal failure.

Dosing in Overweight and Obese Children:

- Dose based on measured body weight.[12]

Renal impairment:

eGFR calculator

- eGFR ≥ 50mL/minute: normal dose
- eGFR ≥ 30 to <50 mL/minute: 10 mg/kg/dose (to a maximum of 500 mg) given 8 hourly
- eGFR ≥ 10 to <30 mL/minute: 10 mg/kg/dose (to a maximum of 500 mg) given 12 hourly
- eGFR < 10mL/minute: 10 mg/kg/dose (to a maximum of 500 mg) given 24 hourly.
- For severe infections, higher doses may be required, contact pharmacy for advice.[3, 9]

Hepatic impairment:

- No dosage adjustment is required in hepatic impairment.[3, 9]

RECONSTITUTION & ADMINISTRATION

Reconstitution:

Oral Cefalexin 250 mg/5 mL:

- Reconstitute with water as follows: tap bottle until all powder flows freely; add approximately half the total volume of water as per the manufacturer's instructions for reconstitution and shake vigorously to suspend powder.[3, 5]
- Add remainder of the water and again shake vigorously. This will result in 100 mL of suspension. Store reconstituted suspension in the refrigerator and discard after 14 days.[3, 5]

Administration:

- When using the oral suspension, shake the bottle well before measuring each dose.[3]
- Cefalexin may be given without regard to food intake.[3, 5, 9]

MONITORING

- Renal, hepatic and haematological function should be monitored with prolonged therapy (i.e. longer than 7 days).[2, 3, 9]

ADVERSE EFFECTS

Common: diarrhoea, nausea, vomiting, abdominal pain, rash, headache, dizziness, eosinophilia, leucopenia, neutropenia.[2, 7]

Infrequent: Anaphylactic reaction, angioedema.[7]

Rare: cholestatic hepatitis, neurotoxicity (confusion, seizures, encephalopathy), Blood dyscrasias (thrombocytopenia, agranular cytosis), nephritis tubulointerstitial, bleeding, renal impairment, severe cutaneous adverse reactions (SCARs).[2, 7]

STORAGE

- Store the capsules below 25 ˚C.(5)
- Store the dry powder below 25˚C, after reconstituting, store between 2˚C and 8˚C and discard after 14 days.[5]

INTERACTIONS

This medication may interact with other medications; consult PCH approved references (e.g. Clinical Pharmacology), a clinical pharmacist or PCH Medicines Information Service on extension 63546 for more information.

Please note: The information contained in this guideline is to assist with the preparation and administration of **cefalexin**. Any variations to the doses recommended should be clarified with the prescriber prior to administration

Related CAHS internal policies, procedures and guidelines

Antimicrobial Stewardship Policy

ChAMP Empiric Guidelines and Monographs
KEMH Neonatal Medication Protocols

References

1. Royal Australian College of General Practitioners, Pharmaceutical Society of Australia, Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. AMH: Children's Dosing Companion. Adelaide: Australian Medicines Handbook Pty Ltd; 2022.
2. Australian Medicines Handbook. Adelaide, S. Aust.: Australian Medicines Handbook; 2025 [cited 2025 30th April]. Available from: https://amhonline-amh-net-au.pklibresources.health.wa.gov.au/.
3. Clinical Pharmacology powered by ClinicalKey [Internet]. Elsvier. 2025 [cited 2025 April 30th]. Available from: https://www-clinicalkey-com.pklibresources.health.wa.gov.au/pharmacology/.
4. Antibiotic Writing Group. Therapeutic Guidelines - Antibiotic. West Melbourne: Therapeutic Guidelines Ltd; 2025. Available from: https://tgldcdp-tg-org-au.pklibresources.health.wa.gov.au/etgAccess.
5. AusDI [Internet]. Health Communication Network Pty Ltd. 2025 [cited 2025 April 30th].
6. IBM Micromedex [Internet]. Truven Health Analytics. 2025 [cited 2025 April 30th]. Available from: http://www-micromedexsolutions-com.pklibresources.health.wa.gov.au/micromedex2/librarian.
7. Paediatric Formulary Committee. BNF for Children: 2025. London: BMJ Group Pharmaceutical Press; 2025.
8. Electronic Medicines Compendium (emc). Surrey: DataPharm Ltd; 2024.
9. Up To Date - Paediatric Drug information [Internet]. Lexicomp. 2025 [cited 2025 April 29th]. Available from: https://www-uptodate-com.pklibresources.health.wa.gov.au/contents/table-of-contents/drug-information/pediatric-drug-information.
10. Gwee A, Autmizguine J, Curtis N, Duffull SB. Twice- and Thrice-daily Cephalexin Dosing for Staphylococcus aureus Infections in Children. Pediatr Infect Dis J. 2020;39(6):519-22.
11. Hikmat S, Boast A, Curtis N, Gwee A. Efficacy and tolerability of high-dose cefalexin 45 mg/kg/dose (maximum 1.5 g) three times daily in children with bone and joint infections. Journal of Antimicrobial Chemotherapy. 2024;80(2):409-12.
12. Kendrick JG, Carr RR, Ensom MH. Pediatric Obesity: Pharmacokinetics and Implications for Drug Dosing. Clin Ther. 2015;37(9):1897-923.

This document can be made available in alternative formats on request.

File Path:	*W:\Safety & Quality\CAHS\CLOVERS MEDICAL Pharmacy\Procedures Protocols and Guidelines\ChAMP\Word*		
Document Owner:	Head of Department – Infectious Diseases		
Reviewer / Team:	Children's Antimicrobial Management Program Pharmacist		
Date First Issued:	September 2013	Last Reviewed:	May 2025
Amendment Dates:	July 2019, June 2020, May 2022, May 2025	Next Review Date:	June 2028
Approved by:	Drugs and Therapeutics Committee	Date:	June 2025
Endorsed by:	Chair, Drugs and Therapeutics Committee	Date:	June 2025
Aboriginal Impact Statement and Declaration (ISD)		Date ISD approved:	August 2023
Standards Applicable:	NSQHS Standards: NSMHS: N/A Child Safe Standards: N/A		

Printed or personally saved electronic copies of this document are considered uncontrolled

Healthy kids, healthy communities

Compassion | Excellence | Collaboration | Accountability | Equity | Respect

Neonatology | Community Health | Mental Health | Perth Children's Hospital